Triple Antiparasitic Therapy of Ivermectin + Fenbendazole + Mebendazole in Cancer: 18 Case Reports (April 2026 Update)

By Editorial Team -

Abstract

Background: Drug repurposing is gaining attention in oncology. Antiparasitic agents such as ivermectin, fenbendazole, and mebendazole have demonstrated preclinical anticancer activity. The potential synergy of these agents as a triple combination is of increasing interest.

Objective: To review mechanistic rationale, preclinical evidence, and human observational data supporting the triple combination of ivermectin, fenbendazole, and mebendazole in cancer and discuss research gaps and limitations.

Methods: Mechanistic studies, preclinical research, and publicly reported case testimonials were reviewed. Human evidence was synthesized using a PRISMA-style framework.

Results: Preclinical studies demonstrate complementary mechanisms of action across all three agents. Five publicly reported cases suggest temporal associations with tumor shrinkage or biomarker improvements, though all are uncontrolled and confounded by prior or concurrent therapies.

Conclusion: While biologically plausible, the ivermectin–fenbendazole–mebendazole combination remains investigational. Observations are hypothesis-generating and warrant controlled preclinical studies and exploratory clinical trials before clinical adoption.



Keywords:

Ivermectin; Fenbendazole; Mebendazole; Drug repurposing; Antiparasitic agents; Cancer therapy; Triple combination therapy; Microtubule inhibition; Metabolic interference; Oncogenic signaling inhibition; Integrative oncology; Case reports; Translational research; Repurposed drug synergy; Experimental cancer treatment.

1. Introduction

Repurposing existing drugs is a promising strategy in oncology due to the high cost and slow development of novel therapeutics. Antiparasitic agents, including ivermectin, fenbendazole, and mebendazole, have independently demonstrated anticancer effects via multiple mechanisms. Preclinical and anecdotal clinical reports suggest potential synergy of these agents when used in combination. This review summarizes mechanistic rationale, preclinical evidence, and publicly reported human observations, with the aim of informing future translational research.

2. Mechanistic Rationale

The triple combination is based on complementary anticancer mechanisms:

  • Microtubule disruption: Fenbendazole and mebendazole inhibit microtubule polymerization, causing mitotic arrest and apoptosis (OneDayMD, 2026).

  • Metabolic interference: Fenbendazole impairs glucose uptake via GLUT1/hexokinase inhibition (OneDayMD). All three anti-parasitic agents i.e. ivermectin, fenbendazole and mebendazole, affect the glycolytic pathway of cancer cells.

  • Oncogenic signaling inhibition: Ivermectin targets STAT3, Wnt/β-catenin, AKT/mTOR, and YAP, potentially enhancing programmed cell death and immune modulation.

  • Anti-angiogenic activity: Mebendazole suppresses VEGF-mediated angiogenesis.

  • Cancer stem cell targeting: Both mebendazole and ivermectin may reduce tumor recurrence and drug resistance.

  • Pharmacokinetic complementarity: Mebendazole has better-established human dosing and bioavailability, whereas fenbendazole is widely available and increasingly reported in anecdotal cases.

This multi-axis interference underpins the hypothesis that the triple combination may produce synergistic anticancer effects.

3. Preclinical Evidence

3.1 In Vitro Studies

  • Ivermectin, fenbendazole, and mebendazole independently inhibit proliferation and induce apoptosis in diverse cancer cell lines.

  • Dual-agent studies show additive effects; triple-agent synergy has not been systematically quantified.

3.2 Animal Models

  • Individual agents reduce tumor growth and metastasis in murine models.

  • Dual-agent studies exist; no triple-agent studies have been reported.

3.3 Comparative Insights

  • Fenbendazole is often highlighted in anecdotal human reports, while mebendazole is more extensively studied preclinically.

  • Both agents share mechanisms including microtubule inhibition, metabolic disruption, and polypharmacological targeting of oncogenic pathways (OneDayMD).

4. Human Observational Evidence: PRISMA Case Series

4.1 Study Identification

  • Five publicly reported cases were identified via social media (X.com) by a single physician.

  • Inclusion criteria: adult patients with histologically confirmed malignancies, use of ≥2 of the three antiparasitic agents, and measurable tumor or biomarker response.

  • No controlled trials met inclusion criteria.

4.2 Case Reports (18 case reports)

Case 18: Stage IV prostate cancer with osseous and lymphatic metastases

  • Had previously self-initiated a 3-month cycling regimen of:

    • Ivermectin

    • Fenbendazole

  • During that period, his PSA levels continued to rise, indicating biochemical progression.

Seeking further intervention, he subsequently began the Dr. George Mark Protocol, implemented alongside conventional oncologic care. The Dr. George Mark structured protocol included:

  • Ivermectin – 72 mg daily

  • Fenbendazole – 444 mg daily

  • Mebendazole – 400 mg daily

Concurrent standard chemoradiation.

After six months of combined therapy:

  • Significant metabolic regression.

  • Resolution of previously active tumor mass.

  • Tumor reduction from approximately 132 cm to no detectable active lesion. (22)

Case 17: Stage 4 Prostate Cancer metastatic to bones (80M, Saudi Arabia)

  • In September 2025 he started Ivermectin and Mebendazole, and then Fenbendazole.

  • Results over 4 months:

    • PSA dropped 1277 to 8.69.

    • “The Clinical response has been remarkable, and my local physician was very surprised by the degree of improvement observed”. (21)

Case 16: Stage 4 Endometrial Cancer spread to bones (65F, Illinois)
  • Ivermectin: 48 mg/day (30 mg a.m. + 18 mg p.m.)
  • Fenbendazole: 888 mg/day )2 X 444 mg capsules), taken daily (7 days/week)
  • Mebendazole: 1000 mg/day (5 x 200 mg capsules), taken daily (7 days/week)
  • Results after 3 months:
    • Vaginal cuff lesion: SUVmax dropped dramatically from 23.3 to 3.3
    • Left obturator lymph node: Essentially resolved.
    • Bone lesions: Remain inactive.
    • No new metastatic disease. 
    • “XXX is feeling noticeably better overall; pelvic pain and vaginal bleeding she was experiencing have resolved”.  (19)
Case 15: Stage 4 Endometrial Cancer metastatic to peritoneum (68F, Canadian)
  • In August 2025 she started:
    • Ivermectin 1mg/kg/day (72mg)
    • Fenbendazole 1500mg/day
  • In October 2025 (CT was improving but not every lesion) she added Mebendazole 1000mg/day.
  • The peritoneal metastasis shrinkage is 60% from the October to December CT scans. (20)
Case 14: Stage 3C Cervical Cancer (35F, Indiana)
  • Ivermectin 1mg/kg/day and Mebendazole 1000mg/day. (switched to Fenbendazole 888mg/day when she ran out of Mebendazole)
  • PET Scan results after 4 months: "Significant improvement with significant decreased size and uptake cervical lesion. Clearing of previous lymph node and left adnexal activity: Cervical lesion is improved. Mass here now measures about 1.5cm previously 5.3cm and now has USV 4.9, previously 17.3". (18)
Case 13 - Early stage Lung Cancer (81F, Canada)
  • Ivermectin + fenbendazole + mebendazole (No chemo)
  • Lung Tumor shrunk by 30% (calculated by Grok). (17)

Case 12 - Stage 4 NSCLC Lung Cancer metastatic to bones and brain (52M, Illinois)

  • Ivermectin + fenbendazole + mebendazole + chemo

  • “CEA numbers have dropped significantly, from 719 at the start to 18 now. Scans also show that the tumors are shrinking and, in some cases, gone. While he still has cancer in the bones, there is much less activity than before.” (16)

Case 11 - Triple Negative Breast Cancer (TNBC) 2.5cm tumor (53F, Georgia)

  • Ivermectin + fenbendazole + mebendazole + chemo.

  • Results after 4 months: Breast lump shrunk and surgery downgraded to lumpectomy. (14)

Case 10 - Stage 4 NSCLC (Non Small Cell Lung Cancer) (51, CZECH REPUBLIC)

  • Ivermectin + fenbendazole; mebendazole added later.

  • Results after 4 months: Lung tumors shrinking. Bone metastases healing. (1)

Case 9 - Stage 4 Tongue Cancer (57F, New York)

  • Ivermectin + mebendaozle; fenbendazole and niclosamide added later.

  • Results after 8 months: 90% of cancer gone. (2)

Case 8 - Stage 4 Hodgkin Lymphoma Un-resectable Pancreatic Cancer (36M, South France)

  • Ivermectin + fenbendazole + mebendazole.

  • Partial response in January 2026 PET scan compared to previous scan from October 2025. (3)

Case 7 - Un-resectable Pancreatic Cancer (43F, Argentina)

  • Ivermectin + fenbendazole; mebendazole added later.

  • Results after 11 months; “CT scan with contrast: pancreas appears normal with no anomalies“. (4)

Case 6 - Stage 4 Prostate Cancer (64M, Spain)

  • Ivermectin + fenbendazole; mebendazole added later

  • Results after 8 months; PET Scan showed improvement in Prostate mass, pelvic nodes, bone metastases and complete resolution of liver metastases. (5)

Case 5 – Stage IV Endometrial Cancer (68F, Canada)

  • Ivermectin + fenbendazole; mebendazole added later

  • Peritoneal metastasis shrank ~60% over 2 months (6).

Case 4 – Stage IV Breast Cancer (66F, California, USA)

  • Triple therapy after discontinuing conventional treatment

  • CA15-3 decline; PET scan showed tumor reduction and resolution of liver metastases (7).

Case 3 – Stage IV Pancreatic Cancer (77M)

  • Fenbendazole + mebendazole

  • CA19-9 decreased from 44,960 to 21; liver lesions resolved or shrank 70–87% (8).

Case 2 – Dual Malignancies: Sarcoma + Neuroendocrine Lung Cancer (61F, Texas, USA)

  • Triple therapy plus pembrolizumab

  • Adrenal sarcoma and lung nodules shrank; other metastases reportedly improved (9).

Case 1 – Stage III NSCLC (59F, South Carolina, USA)

  • Triple therapy plus itraconazole, doxycycline, CBD, DMSO

  • Primary tumor volume reduced ~89–91%; lymph nodes shrank (10).

4.3 Limitations

  • All reports are uncontrolled observational data.
  • Potential reporting bias; confounding by prior or concurrent therapies.
  • Small sample size; variable follow-up (3–11 months).

5. Discussion

5.1 Integration of Mechanistic, Preclinical, and Case Evidence

  • Mechanistic studies support multi-target anticancer activity.

  • Case reports suggest potential signals of tumor or biomarker response.

  • Observed responses appear more pronounced with all three agents combined, supporting potential synergy.

5.2 Research Implications

  • Preclinical triple-agent synergy studies and pharmacokinetic modeling are needed.

  • Adaptive pilot trials or N-of-1 studies could inform safety, dosing, and efficacy.

5.3 Limitations

  • No controlled clinical trials; causality cannot be established.

  • Case reports are anecdotal and unverified.

  • Safety of chronic high-dose combination remains unknown.

  • Drug interactions with conventional therapies are not defined.

5.4 Risk–Benefit Considerations

High Potential Upside:

  • Measurable tumor regression or biomarker reductions in multiple cancers.

  • Multi-pathway synergy increases likelihood of response.

  • Potential activity in traditionally refractory cancers.

Low Potential Downside:

  • Established safety profiles for approved doses of all three agents.

  • Oral administration, inexpensive, widely available.

  • Sequential dosing allows monitoring of tolerability.

  • Risks: Liver strain. Monitor Liver Function Tests. 

Caveats:

  • Safety in chronic high-dose use is unknown.

  • Evidence is anecdotal; causality is unproven.

  • Potential drug interactions are undefined.

Summary: Early reports suggest a high potential upside with relatively low reported downside, justifying systematic investigation.

6. Conclusion

The ivermectin–fenbendazole–mebendazole combination (IFM) is biologically plausible, supported by preclinical evidence, and temporally associated with anecdotal tumor or biomarker responses. Evidence is low quality and uncontrolled; it cannot guide clinical practice. Favorable hypothetical risk–benefit considerations support further preclinical studies and exploratory clinical trials to assess safety, dosing, and efficacy.


7. References

  1. William Makis. 51 year old Engineer from CZECH REPUBLIC with Stage 4 NSCLC Lung Cancer. X.com (Feb 2026)

  2. William Makis. 57 year old New York woman with Stage 4 Tongue Cancer.

    X.com (Jan 2026)

  3. William Makis. 36 year old man in South France with Stage 4 Hodgkin Lymphoma. X.com (Feb 2026)

  4. William Makis. 43 year old Argentina woman from Quebec with un-resectable Pancreatic Cancer. X.com (Jan 2026)

  5. William Makis. 64 year old man from SPAIN with Stage 4 Prostate Cancer. X.com (Jan 2026)

  6. William Makis. 68 year old Canadian woman with Stage 4 Endometrial Cancer metastatic to peritoneum. X.com (Jan 2026)

  7. William Makis. 66 year old California Woman with metastatic Stage 4 Breast Cancer. X.com (Dec 2025)

  8. William Makis. 77 year old Stage 4 Pancreatic Cancer. X.com (Apr 2025)

  9. William Makis. 61 year old Texas woman with 2 cancers: Sarcoma of arm metastatic to adrenal, and Neuroendocrine Cancer of the Lung. X.com (Aug 2025)

  10. William Makis. 59 year old South Carolina woman with Stage 3 NSCLC Lung Cancer. X.com (Dec 2025)

  11. OneDayMD. (2026, Jan). Fenbendazole vs. Mebendazole: What is the difference? https://www.onedaymd.com/2023/12/fenbendazole-vs-mebendazole-what-is.html

  12. OneDayMD. (2026, Mar). Ivermectin, fenbendazole and mebendazole cancer success stories: 590+ Case reports. https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html

  13. OneDayMD. (2026, Mar). Stage 4 Cancer Remissions with Fenbendazole, Ivermectin and Mebendazole: 300+ Case Reports Compilation. https://www.onedaymd.com/2025/06/ivermectin-fenbendazole-mebendazole-stage-4-cancer.html

  14. William Makis. 53 year old GEORGIA woman with Triple Negative Breast Cancer (TNBC) 2.5cm tumor. X.com (Feb 2026).

  15. Enhanced Ivermectin and Mebendazole Protocol: A 16-Week Integrative Orthomolecular Approach Targeting Mitochondrial Dysfunction and CancerStem Cells in Resistant and Metastatic Cancers (2026)

  16. William Makis. 52 year old Illinois man with Stage 4 NSCLC Lung Cancer metastatic to bones and brain. X.com (February 2026).

  17. William Makis. 81-yr-old Canadian woman with early stage Lung Cancer (No Chemo). X.com (February 2026)

  18. Dr. William Makis. 35 year old INDIANA woman with Stage 3C Cervical Cancer. X.com* (February 2026)

  19. Dr. William Makis. 65 year old Illinois woman with Stage 4 Endometrial Cancer to bones. X.com (March 2026)

  20. Dr. William Makis. 68 year old Canadian woman with Stage 4 Endometrial Cancer metastatic to peritoneum. X.com* (January 2026)

  21. Dr William Makis. 80 year old man in SAUDI ARABIA with Stage 4 Prostate Cancer metastatic to bones. X.com (February 2026)

  22. Dr George Mark. A male patient diagnosed with Stage IV prostate cancer with osseous and lymphatic metastases. X.com (February 2026)


*Important update: Most of the X.com (formerly Twitter) links from Dr William Makis now appear to be broken or inaccessible. This may be related to legal actions or regulatory proceedings involving Canadian authorities, although the exact reason for the link removals is not publicly clear. As a result, many of the original posts that were previously shared or cited on X.com are no longer available through their original links. The vast majority of the case reports, testimonials, and cancer-related discussions originally shared on X are mirrored (and actively updated) on his Substack: makisw.substack.com (published as "COVID Intel - by William Makis" / McGill Medicine branding).

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Fenbendazole, Ivermectin and Mebendazole for Cancer: A Case Series of 708 Case Reports (April 2026 Update)

By Editorial Team -
Image
Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories  (115 cases) Brain Cancer (including Glioblastoma) (120 cases) Bile Duct Cancer (Cholangiocarcinoma)  (4 cases) Bladder Cancer Success Stories  (including kidney cancer) (32 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (57 cases) Esophageal and Stomach cancer (23 cases) Endometrial Cancer (11 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer ) (22 cases) Head and Neck Cancer (15 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) (32 cases) Liver Cancer (HepatoCellular Cancer)  (3 cases) Lung Cancer (43 cases) Leukemia (9 cases) Lymphoma (23 cases) Melanoma (refer to Skin Cancer ) ...
Read more

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

By Editorial Team -
Image
Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Updated version I have an article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Yuan Yuan et al (Cedars-Sinai Medical Center) - A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer (ASCO 2025) Hulscher et al -  Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer ...
Read more

Ivermectin, Fenbendazole and Mebendazole Protocol in Cancer: Peer-Reviewed Protocol in Cancer

By Editorial Team -
Image
Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against c...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

By Editorial Team -
Image
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed wit...
Read more

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

By Editorial Team -
Image
Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) runs the world's largest high-dose ivermectin cancer clientele in 2025 – he has guided thousands of patients globally with remarkable results in turbo cancers and conventional failures. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. ...
Read more

Ivermectin Tested against 28 types of Cancer: Most Sensitive vs Least Sensitive

By Editorial Team -
Image
A research group from Mexico investigated Ivermectin in Cancer. This is the first study that has tested as many as 28 Cancer types with Ivermectin.  Paper: 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.  Ivermectin was tested at 2mg/kg/day which translates to roughly 5uM in vitro concentration. The most sensitive cancer cell lines were: 1. Ovarian 2. Breast 3. Glioblastoma 4. Lung Cancer 5. Colon Cancer 6. Uterine SCC 7. hepatocellular 8. breast TNBC 9. Pancreatic 10. Endometrial. Least sensitive were: 1. osteosarcoma 2. gastric 3. melanoma  Although lymphoma and leukemia cell lines appear to be more resistant to Ivermectin, Ivermectin has a significant impact on those cells' ability to form colonies. So yes, Ivermectin is useful against BOTH lymphomas and leukemias.  Ivermectin also goes after CANCER STEM CELLS, which tend to be resistant to chemotherapy: ...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

By Editorial Team -
Image
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses.  Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to the  current weight, the type of Cancer, the stage and grade of the Cancer and the health of the liver. Ivermectin dosage should also be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. It also takes into account the types of medications the person uses. For example, i...
Read more

Ivermectin Dosage Guide for Humans (2026)

By Editorial Team -
Image
In this Article : Overview of Ivermectin Dosage | Ivermectin Dosage for Adults | Ivermectin Dosage for Children | Ivermectin dosage restrictions | How to take ivermectin | Ivermectin dosage FAQs The prescribed dosage for ivermectin oral tablets depends on the type of parasitic infection you have and your body weight. Ivermectin is typically taken as a single dose. Repeat doses may be needed in some cases. Specifically, ivermectin oral tablet is approved by the Food and Drug Administration (FDA) to treat the following conditions in adults and certain children: a parasitic infection in the intestinal tract called strongyloidiasis a parasitic infection of the eyes and skin called onchocerciasis  (River Blindness) Ivermectin oral tablet is a generic medication and belongs to a drug class called antiparasitic medications. It is also available in a brand-name version called Stromectol. This article describes the dosages of ivermectin oral tablets, as well as the medication’s stren...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

By Editorial Team -
Image
In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I decided that I will make that decision,” she said, “only if it’s the last resort, and I’m on my deathbed.” A few months before her consultation, however, Eyres, then fifty-eight, made an appointment with a new primary care doctor for routine prescription refills. She was about to be introduced, literally and figuratively, to a new kind of medicine. It would change everything. DMSO Online Buying Guide (Paid Link) Buy on Amazon Disclosure: OneDayMD.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program that enables sites to earn advertising fees by advertising and linking to Amazon.com, but this is at NO extra cost t...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

By Editorial Team -
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 500 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more